NT-pro-BNP in patients with left ventricular hypertrabeculation/non-compaction.
Biomarkers
Cardiomyopathy
Echocardiography
Heart failure
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
revised:
03
09
2020
received:
23
05
2020
accepted:
09
09
2020
pubmed:
24
9
2020
medline:
24
9
2020
entrez:
23
9
2020
Statut:
ppublish
Résumé
Left ventricular hypertrabeculation/non-compaction (LVHT) is a cardiac abnormality of unknown pathogenesis and frequently associated with neuromuscular disorders. The N-terminal fragment of the pro brain natriuretic peptide (NT-pro-BNP) is a prognostic marker in heart failure whose relevance in LVHT patients is largely unknown. The aim of the study was to assess the role of NT-pro-BNP levels as prognostic markers in LVHT. Data of LVHT patients were collected in a database from one echocardiographic laboratory since 1996. The hospital information system was screened for measurements of NT-pro-BNP levels, and their association with clinical and echocardiographic baseline parameters was retrospectively assessed. During follow-up, the endpoints were death and heart transplantation. In 113 patients (median age 57 years, 24% women), data about NT-pro-BNP measurements were found, ranging from 8 to 121 152 (median 2029) ng/L. High NT-pro-BNP levels were associated with heart failure, valvular abnormalities, diabetes mellitus, hypertension, angina pectoris, number of LVHT-affected segments, end-diastolic diameter, and systolic dysfunction. During a follow-up of 73 (±64; 0-237) months, 35% of the patients reached an endpoint. High NT-pro-BNP levels were associated with the occurrence of an endpoint (P < 0.001). By multivariate analysis, predictors for endpoints were increased age (P = 0.0025), atrial fibrillation (P = 0.0023), natural logarithm of NT-pro-BNP levels (P = 0.0073), diabetes mellitus (P = 0.014), and thromboembolic events before diagnosis (P = 0.0347). Also in LVHT patients, high NT-pro-BNP levels are indicators for death and heart transplantation.
Identifiants
pubmed: 32964696
doi: 10.1002/ehf2.13029
pmc: PMC7754902
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4126-4133Informations de copyright
© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
Références
Stöllberger C, Finsterer J. Left ventricular hypertrabeculation/noncompaction. J Am Soc Echocardiogr 2004; 17: 91-100.
Gati S, Rajani R, Carr-White GS, Chambers JB. Adult left ventricular noncompaction: reappraisal of current diagnostic imaging modalities. JACC Cardiovasc Imaging 2014; 7: 1266-1275.
Bennett CE, Freudenberger R. The current approach to diagnosis and management of left ventricular noncompaction cardiomyopathy: review of the literature. Cardiol Res Pract 2016: 5172308. https://doi.org/10.1155/2016/5172308
Finsterer J, Stöllberger C, Towbin JA. Left ventricular noncompaction cardiomyopathy: cardiac, neuromuscular and genetic factors. Nat Rev Cardiol 2017; 14: 224-237.
Stöllberger C, Blazek G, Gessner M, Bichler K, Wegner C, Finsterer J. Neuromuscular comorbidity, heart failure, and atrial fibrillation as prognostic factors in left ventricular hypertrabeculation/noncompaction. Herz 2015; 40: 906-911.
Finsterer J. Left ventricular non-compaction and its cardiac and neurologic implications. Heart Fail Rev 2010; 15: 589-603.
van Waning JI, Caliskan K, Hoedemaekers YM, van Spaendonck-Zwarts KY, Baas AF, Boekholdt SM, van Melle JP, Teske AJ, Asselbergs FW, Backx APCM, du Marchie Sarvaas GJ, Dalinghaus M, Breur JMPJ, Linschoten MPM, Verlooij LA, Kardys I, Dooijes D, Lekanne Deprez RH, Upma AS, van den Berg MP, Hofstra RMW, van Slegtenhorst MA, Jongbloed JDH, Majoor-Krakauer D. Genetics, clinical features, and long-term outcome of noncompaction cardiomyopathy. J Am Coll Cardiol 2018; 71: 711-722.
Tian T, Liu Y, Gao L, Wang J, Sun K, Zou Y, Wang L, Zhang L, Li Y, Xiao Y, Song L, Zhou X. Isolated left ventricular noncompaction: clinical profile and prognosis in 106 adult patients. Heart Vessels 2014; 29: 645-652.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-2200.
Vanderheyden M, Bartunek CG, Manoharan G, Beckers JF, Ide L. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction. Clin Biochem 2006; 39: 640-645.
Stämpfli SF, Erhart L, Hagenbuch N, Stähli BE, Gruner C, Greutmann M, Niemann M, Kaufmann BA, Jenni R, Held L, Tanner FC. Prognostic power of NT-proBNP in left ventricular non-compaction cardiomyopathy. Int J Cardiol 2017; 236: 321-327.
Analytics M. COBAS proBNP II. 2016;V 9.0.
Malli N, Wilfinger-Lutz N, Krugluger W, Stöllberger C, Winkler-Dworak M, Finsterer J. Prognostic role of pro-BNP levels in left ventricular hypertrabeculation/non-compaction and neuromuscular disorders: results of a pilot study. Minerva Cardioangiol 2019; 67: 254-256.
Gao XJ, Kang LM, Zhang J, Jiang Y, Zhao SH, Lu MJ, Cheng HB, Luo XL, Jiang W, Lü R, Zhu J, Yang YJ. Incidence of coronary artery disease and outcome of patients with left ventricular noncompaction. Zhonghua Xin Xue Guan Bing Za Zhi 2011; 39: 725-729.
Stöllberger C, Hasun M, Winkler-Dworak M, Finsterer J. Usefulness of neuromuscular comorbidity, left bundle branch block and atrial fibrillation to predict the long-term prognosis of left ventricular hypertrabeculation/noncompaction. Am J Cardiol 2020; 128: 168-173.
Mills M. Introducing survival and event history analysis. London: Sage Publications; 2011.
Hosmer DW, Lemeshow S, Kim S. Applied Survival Analysis: Regression Modeling of Time-to-Event Data. Hoboken, NJ: John Wiley & Sons, Inc; 2008.
StataCorp. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC; 2019.
Cerar A, Jaklic M, Frljak S, Poglajen G, Zemljic G, Guzic Salobir B, Dolenc Novak M, Stalc M, Zbacnik R, Kozelj M. Impairment of myocardial perfusion correlates with heart failure severity in patients with non-compaction cardiomyopathy. ESC Heart Fail 2020; 7: 1161-1167.
Tizón-Marcos H, de la Paz RM, Pibarot P, Bertrand O, Bibeau K, Le Ven F, Sinha S, Engert J, Bédard E, Pasian S, Deschepper C, Larose E. Characteristics of trabeculated myocardium burden in young and apparently healthy adults. Am J Cardiol 2014; 114: 1094-1099.
Marchal P, Lairez O, Cognet T, Chabbert V, Barrier P, Berry M, Méjean S, Roncalli J, Rousseau H, Carrié D, Galinier M. Relationship between left ventricular sphericity and trabeculation indexes in patients with dilated cardiomyopathy: a cardiac magnetic resonance study. Eur Heart J Cardiovasc Imaging 2013; 14: 914-920.
Misumi I, Nishida Y, Honda T, Kurokawa H, Yasuda H, Kaikita K, Hokimoto S, Ogawa H. Markedly high B-type natriuretic peptide level in a patient with Duchenne muscular dystrophy and left ventricular non-compaction. Intern Med 2015; 54: 2197-2200.
Stöllberger C, Winkler-Dworak M, Blazek G, Finsterer J. Left ventricular hypertrabeculation/noncompaction with and without neuromuscular disorders. Int J Cardiol 2004; 97: 89-92.